4.3 Article

Gaps in the Care of Familial Hypercholesterolaemia in Australia: First Report From the National Registry

Journal

HEART LUNG AND CIRCULATION
Volume 30, Issue 3, Pages 372-379

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.hlc.2020.07.012

Keywords

Familial hypercholesterolaemia; Lipids; Cardiovascular disease; Treatment; Targets; Registry

Funding

  1. Amgen
  2. MSD
  3. Sanofi
  4. WAHTN Early Career Fellowship
  5. Australian Government's Medical Research Future Fund

Ask authors/readers for more resources

Analysis of the FH Australasia Network registry revealed that patients are typically identified later in life, have a high burden of coronary artery disease, and do not achieve guideline-recommended LDL-cholesterol targets. Genetic and cascade testing are under-utilised, highlighting the need for improved care strategies as a public health priority.
Background Familial hypercholesterolaemia (FH) is under-diagnosed and under-treated worldwide, including Australia. National registries play a key role in identifying patients with FH, understanding gaps in care and advancing the science of FH to improve care for these patients. Methods The FH Australasia Network has established a national web-based registry to raise awareness of the condition, facilitate service planning and inform best practice and care services in Australia. We conducted a cross-sectional analysis of 1,528 FH adults enrolled in the registry from 28 lipid clinics. Results The mean age at enrolment was 53.4 +/- 15.1 years, 50.5% were male and 54.3% had undergone FH genetic testing, of which 61.8% had a pathogenic FH-causing gene variant. Only 14.0% of the cohort were family members identified through cascade testing. Coronary artery disease (CAD) was reported in 28.0% of patients (age of onset 49.0 +/- 10.5 years) and 64.9% had at least one modifiable cardiovascular risk factor. The mean untreated LDL-cholesterol was 7.4 +/- 2.5 mmol/L. 80.8% of patients were on lipid-lowering therapy with a mean treated LDL-cholesterol of 3.3 +/- 1.7 mmol/L. Among patients receiving lipid-lowering therapies, 25.6% achieved an LDL-cholesterol target of <2.5 mmol/L without CAD or <1.8 mmol/L with CAD. Conclusion Patients in the national FH registry are detected later in life, have a high burden of CAD and risk factors, and do not achieve guideline-recommended LDL-cholesterol targets. Genetic and cascade testing are under-utilised. These deficiencies in care need to be addressed as a public health priority.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available